^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAR19-CYNK

    i
    Other names: CAR19-CYNK
    Associations

    News

    Trials
    Company:
    Celularity
    Drug class:
    CD19 inhibitor, NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    over2years
    Development of CD19 CAR Engineered Human Placental CD34+-Derived Natural Killer Cells (CAR19-CYNK) As an Allogeneic Cancer Immunotherapy (ASH 2021)
    Luciferase expressing Daudi cells (3×10 6 ) were intravenously (IV) injected on Day 0 three days after the mice were preconditioned with a myeloablative dose of busulfan to allow for better tumor cell engraftment... In summary, we have successfully established a process for generating CAR19-CYNK cells from human placental CD34 + cells. CAR19-CYNK demonstrated enhanced in vitro cytotoxicity against CD19 + B cell malignancies and in vivo survival benefit in a disseminated lymphoma xenograft B-NDG-hIL15 model. Further development of CAR19-CYNK for CD19 + B cell malignancies is warranted.
    IO biomarker
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • CSF2 (Colony stimulating factor 2) • NKG2D (killer cell lectin like receptor K1)
    |
    CD19 expression
    |
    busulfan • CAR19-CYNK • ROR1.TNK